Publications in collaboration with researchers from GlaxoSmithKline (United Kingdom) (6)

2014

  1. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: An open-label, multicenter, single-arm, Phase II study

    Journal of Infectious Diseases

2013

  1. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: Results from the randomised, placebo-controlled avodart after radical therapy for Prostate Cancer Study (ARTS)

    European Urology, Vol. 63, Núm. 5, pp. 779-787

  2. Reply from authors re: Behfar Ehdaie, Karim A. Touijer. 5-Alpha reductase inhibitors in prostate cancer: From clinical trials to clinical practice. Eur Urol 2013;63:788-9: 5-Alpha reductase inhibitors in prostate cancer

    European Urology

2004

  1. Cardiovascular effects of the nitric oxide synthase inhibitor N G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)

    Critical Care Medicine, Vol. 32, Núm. 1, pp. 13-20

  2. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock

    Critical Care Medicine, Vol. 32, Núm. 1, pp. 21-30

1999

  1. Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock

    Critical Care Medicine, Vol. 27, Núm. 1 SUPPL.